CTIS2023-508506-22-00进行中（未招募）1 期
A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease - NN7533-4470
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age above or equal to 18 years at the time of signing informed consent, Confirmed diagnosis of SCD (including HbSS, HbSC, HbSß0 thalassaemia and HbSß+ thalassaemia or other Sickle Cell disease variants), 2–10 episodes of documented VOCs within the last 12 months prior to the screening visit, Haemoglobin =5.0 g/dL and =10.5 g/dL at visit 1, Absolute reticulocyte (absolute) count above ULN at visit 1, Body weight 40 to 125 kg (inclusive)
排除标准
- •Patient is on chronic transfusion therapy as defined by receiving scheduled (pre-planned) series of blood transfusion (simple or exchange) for prophylactic purposes, or the patient is likely to begin chronic transfusion therapy during the course of the trial, or has received RBC or whole blood transfusion for any reason within 28 days of visit 1, Male with female partner of childbearing potential who does not agree to use condom and whose female partner of childbearing potential is not using a highly effective contraceptive measure from trial start to Six (6) months after the last dose of trial product for patients outside US and CA randomised to HU, Male with female partner of childbearing potential who does not agree to use condom and whose female partner of childbearing potential is not using a highly effective contraceptive measure from trial start to Twelve (12) months after the last dose of trial product for patients randomised to HU in US and CA, Receipt of erythropoietin or other haematopoietic growth factor treatment within 28 days of signing ICF, or planned treatment with these agents during the trial, Receipt of voxelotor, crizanlizumab or L-glutamine treatment within 12 weeks of signing the informed consent form, or planned treatment with such agents during the trial, Platelet count >800 x 10^9/L at visit 1, Absolute neutrophil count =1.5 x 10^9/L at visit 1, Any condition/concurrent chronic disease involving the stomach or small intestine which may affect drug absorption, as per investigator's judgement, Female who is: pregnant, breast-feeding or intends to become pregnant within 6 months after the final trial product administration or, Female who is: child-bearing potential and not using highly effective methods of contraception and whose male partner is not using effective contraception, at screening and until 6 months after the last dose of trial product, Male with female partner of childbearing potential who does not agree to use condom and whose female partner of childbearing potential is not using a highly effective contraceptive measure from trial start to Six (6) months after the last dose of trial product for patients on NDec/Placebo
研究者
相似试验
尚未招募
2 期
ACENT 1Patients with Sickle Cell Disease.Sickle cell disease (SCD) Foetal haemoglobin (HbF) mutated sickle cell haemoglobin (HbS)LBCTR2024015480ovo Nordisk87
已完成
2 期
Research study investigating how well NDec works in people with sickle cell diseaseSickle cell disease2023-508506-22-00Novo Nordisk A/S15
进行中（未招募）
2 期
Research study investigating how well NDec works in people with sickle cell diseaseCTRI/2023/01/049275ovo Nordisk AS
已完成
不适用
Multicentric clinical trial on the efficacy and safety of ceftriaxone and sulbactam in lower respiratory tract infectioower respiratory tract infectionInfections and InfestationsRespiratory tract infectionISRCTN51896330Venus Remedies Limited (India)105
尚未招募
不适用
A multicenter clinical study to test the efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism.clinical amnitotic fluid embolismJPRN-UMIN000012273Department of Obstetrics and Gynecology, Mie university hospital.5